{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:19:28Z","timestamp":1788477568047,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00535-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:24:15Z","timestamp":1781839455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A rare case of fulminant talquetamab-induced myocarditis presenting as a STEMI mimicker"],"prefix":"10.1186","volume":"12","author":[{"given":"Eric J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Diaz","family":"Saravia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"24","key":"535_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, Donk NWCJ, van de, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"key":"535_CR2","doi-asserted-by":"publisher","unstructured":"Cohen YC, Moreau P, Tolbert J, Qin X, Ma X, Vieyra D et al. MonumenTAL-3: Phase 3 Trial of Talquetamab\u2009+\u2009Daratumumab\u2009\u00b1\u2009Pomalidomide Versus Daratumumab\u2009+\u2009Pomalidomide\u2009+\u2009Dexamethasone in Relapsed\/Refractory Multiple Myeloma Following\u2009\u2265\u20091 Prior Line of Therapy. Blood. 2022;Annual Meeting Abstracts140:4418\u20139. https:\/\/doi.org\/10.1182\/blood-2022-162733.","DOI":"10.1182\/blood-2022-162733"},{"issue":"15","key":"535_CR3","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, et al. A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343. https:\/\/doi.org\/10.1182\/blood.2019003342 . PubMed PMID: 32040549; PubMed Central PMCID: PMC7146017.","journal-title":"Blood"},{"issue":"8","key":"535_CR4","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805 . PubMed PMID: 33890981; PubMed Central PMCID: PMC8095149.","journal-title":"Blood Adv"},{"key":"535_CR5","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205:114075. https:\/\/doi.org\/10.1016\/j.ejca.2024.114075.","journal-title":"Eur J Cancer"},{"issue":"3","key":"535_CR6","doi-asserted-by":"publisher","first-page":"e190010","DOI":"10.1148\/ryct.2019190010","volume":"1","author":"JA Luetkens","year":"2019","unstructured":"Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A, et al. Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort. Radiol Cardiothorac Imaging. 2019;1(3):e190010. https:\/\/doi.org\/10.1148\/ryct.2019190010.","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"41","key":"535_CR7","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"36","key":"535_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211 . PubMed PMID: 27567406.","journal-title":"Eur Heart J"},{"issue":"16","key":"535_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJMra2114478","volume":"387","author":"C Basso","year":"2022","unstructured":"Basso C, Myocarditis. N Engl J Med. 2022;387(16):1488\u2013500. https:\/\/doi.org\/10.1056\/NEJMra2114478.","journal-title":"N Engl J Med"},{"key":"535_CR10","doi-asserted-by":"publisher","first-page":"e00702","DOI":"10.1016\/j.idcr","volume":"19","author":"J Chow","year":"2020","unstructured":"Chow J, Murphy J, Subedi A, Jyothidasan A. Rhinovirus-associated dilated cardiomyopathy. IDCases. 2020;19:e00702. https:\/\/doi.org\/10.1016\/j.idcr. .2020.e00702 PubMed PMID: 32021801; PubMed Central PMCID: PMC6992979.","journal-title":"IDCases"},{"key":"535_CR11","doi-asserted-by":"publisher","first-page":"1643502","DOI":"10.3389\/fimmu.2025.1643502","volume":"16","author":"J Xu","year":"2025","unstructured":"Xu J, Chen X, Guan X, Zhang H, Liu Y, Zhang M. Therapeutic frontiers in viral myocarditis: targeting inflammation, viruses, oxidative stress, and myocardial repair. Front Immunol. 2025;16:1643502. https:\/\/doi.org\/10.3389\/fimmu.2025.1643502 . PubMed PMID: 40895553; PubMed Central PMCID: PMC12390813.","journal-title":"Front Immunol"},{"issue":"10","key":"535_CR12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune Checkpoint Inhibitor\u2013Induced Cardiotoxicity. JAMA Oncol. 2024;10(10):1390\u20139. https:\/\/doi.org\/10.1001\/jamaoncol. 2024.3065 PubMed PMID: 39172480; PubMed Central PMCID: PMC11342217.","journal-title":"JAMA Oncol"},{"issue":"2","key":"535_CR13","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024;12(2):e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518 . PubMed PMID: 38388168; PubMed Central PMCID: PMC10882360.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"535_CR14","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.4049\/jimmunol.1901401","volume":"204","author":"C Godbersen-Palmer","year":"2020","unstructured":"Godbersen-Palmer C, Coupet TA, Grada Z, Zhang SC, Sentman CL. Toxicity induced by a bispecific T cell redirecting protein is mediated by both T cells and myeloid cells in immunocompetent mice. J Immunol Baltim Md 1950. 2020;204(11):2973\u201383. https:\/\/doi.org\/10.4049\/jimmunol.1901401 . PubMed PMID: 32295875; PubMed Central PMCID: PMC7304495.","journal-title":"J Immunol Baltim Md 1950"},{"key":"535_CR15","doi-asserted-by":"publisher","unstructured":"Leclercq G, Servera LA, Danilin S, Challier J, Steinhoff N, Bossen C et al. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology 11(1):2039432. https:\/\/doi.org\/10.1080\/2162402X.2022.2039432. PubMed PMID: 35186442; PubMed Central PMCID: PMC8855852.","DOI":"10.1080\/2162402X.2022.2039432"},{"issue":"4","key":"535_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.70004","volume":"118","author":"J Gong","year":"2025","unstructured":"Gong J, Zhou J, Yuan D, Ma X, Vishwamitra D, Hilder B, et al. Recommended Phase II Doses of Talquetamab in Patients With Relapsed\/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results. Clin Pharmacol Ther. 2025;118(4):954\u201366. https:\/\/doi.org\/10.1002\/cpt.70004 . PubMed PMID: 40704375; PubMed Central PMCID: PMC12439005.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"535_CR17","doi-asserted-by":"publisher","first-page":"e12726","DOI":"10.1111\/anec.12726","volume":"25","author":"C Butt\u00e0","year":"2019","unstructured":"Butt\u00e0 C, Zappia L, Laterra G, Roberto M. Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review. Ann Noninvasive Electrocardiol. 2019;25(3):e12726. https:\/\/doi.org\/10.1111\/anec.12726 . PubMed PMID: 31778001; PubMed Central PMCID: PMC7958927.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"3","key":"535_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ajem.2008.12.017","volume":"28","author":"M Punja","year":"2010","unstructured":"Punja M, Mark DG, McCoy JV, Javan R, Pines JM, Brady W. Electrocardiographic manifestations of cardiac infectious-inflammatory disorders. Am J Emerg Med. 2010;28(3):364\u201377. https:\/\/doi.org\/10.1016\/j.ajem.2008.12.017.","journal-title":"Am J Emerg Med"},{"key":"535_CR19","doi-asserted-by":"publisher","unstructured":"Yildiz M, Ashokprabhu N, Shewale A, Pico M, Henry TD, Quesada O. Myocardial infarction with non-obstructive coronary arteries (MINOCA). Front Cardiovasc Med. 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.1032436.","DOI":"10.3389\/fcvm.2022.1032436"},{"issue":"3","key":"535_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/s0735-1097","volume":"37","author":"L Sarda","year":"2001","unstructured":"Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol. 2001;37(3):786\u201392. https:\/\/doi.org\/10.1016\/s0735-1097. (00)01201-8 PubMed PMID: 11693753.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"535_CR21","first-page":"256","volume":"33","author":"JM Testani","year":"2006","unstructured":"Testani JM, Kolansky DM, Litt H, Gerstenfeld EP. Focal Myocarditis Mimicking Acute ST-Elevation Myocardial Infarction. Tex Heart Inst J. 2006;33(2):256\u20139. PubMed PMID: 16878641; PubMed Central PMCID: PMC1524714.","journal-title":"Tex Heart Inst J"},{"issue":"1","key":"535_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0735-1097(92","volume":"20","author":"GW Dec","year":"1992","unstructured":"Dec GW, Waldman H, Southern J, Fallon JT, Hutter AM, Palacios I. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol. 1992;20(1):85\u20139. https:\/\/doi.org\/10.1016\/0735-1097(92. )90141-9 PubMed PMID: 1607543.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"535_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/0002-8703","volume":"115","author":"CL Miklozek","year":"1988","unstructured":"Miklozek CL, Crumpacker CS, Royal HD, Come PC, Sullivan JL, Abelmann WH. Myocarditis presenting as acute myocardial infarction. Am Heart J. 1988;115(4):768\u201376. https:\/\/doi.org\/10.1016\/0002-8703. )90877-0 PubMed PMID: 3354405.","journal-title":"Am Heart J"},{"issue":"17","key":"535_CR24","doi-asserted-by":"publisher","first-page":"e031454","DOI":"10.1161\/JAHA.123.031454","volume":"12","author":"P Martens","year":"2023","unstructured":"Martens P, Cooper LT, Tang WHW. Diagnostic Approach for Suspected Acute Myocarditis: Considerations for Standardization and Broadening Clinical Spectrum. J Am Heart Assoc. 2023;12(17):e031454. https:\/\/doi.org\/10.1161\/JAHA.123.031454.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"535_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10741-019-09835-9","volume":"25","author":"JL Katzmann","year":"2020","unstructured":"Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M, et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Fail Rev. 2020;25(2):277\u201394. https:\/\/doi.org\/10.1007\/s10741-019-09835-9.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"535_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab","volume":"43","author":"J Herrmann","year":"2021","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2021;43(4):280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab. 674 PubMed PMID: 34904661; PubMed Central PMCID: PMC8803367.","journal-title":"Eur Heart J"},{"issue":"10","key":"535_CR27","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune Checkpoint Inhibitor\u2013Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10(10):1390\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3065.","journal-title":"JAMA Oncol"},{"issue":"Supplement6","key":"535_CR28","doi-asserted-by":"publisher","first-page":"suaf083165","DOI":"10.1093\/eurheartjsupp\/suaf083.165","volume":"27","author":"S Jimenez-Marrero","year":"2025","unstructured":"Jimenez-Marrero S, Feliu M, Pons Riverola A, Morillas H, Ramos R, Garay A, et al. Mycophenolate mofetil as second-line therapy for steroid-refractory ICI-induced myocarditis. Eur Heart J Suppl. 2025;27(Supplement6):suaf083165. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suaf083.165.","journal-title":"Eur Heart J Suppl"},{"issue":"9","key":"535_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31(9):1273\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.005 . PubMed PMID: 32425357; PubMed Central PMCID: PMC7229714.","journal-title":"Ann Oncol"},{"issue":"35","key":"535_CR30","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.jaccas.2025.105543","volume":"30","author":"T Vockenhuber","year":"2025","unstructured":"Vockenhuber T, Baldinger L, Clausen J, Kollias G, Schmid M, Schneiderbauer-Porod S, et al. Successful Use of Ruxolitinib for Steroid-Refractory Immune Checkpoint Inhibitor\u2013Associated Myocarditis. JACC Case Rep. 2025;30(35):105543. https:\/\/doi.org\/10.1016\/j.jaccas.2025.105543.","journal-title":"JACC Case Rep"},{"issue":"24","key":"535_CR31","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for Severe Immune Checkpoint Inhibitor\u2013Associated Myocarditis. N Engl J Med. 2019;380(24):2377\u20139. https:\/\/doi.org\/10.1056\/NEJMc1901677.","journal-title":"N Engl J Med"},{"issue":"2","key":"535_CR32","doi-asserted-by":"publisher","first-page":"ytaf019","DOI":"10.1093\/ehjcr\/ytaf019","volume":"9","author":"E Wadden","year":"2025","unstructured":"Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, et al. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. Eur Heart J - Case Rep. 2025;9(2):ytaf019. https:\/\/doi.org\/10.1093\/ehjcr\/ytaf019.","journal-title":"Eur Heart J - Case Rep"},{"issue":"1","key":"535_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-025-01261-5","volume":"15","author":"S Palfi","year":"2025","unstructured":"Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, et al. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025;15(1):63. https:\/\/doi.org\/10.1038\/s41408-025-01261-5.","journal-title":"Blood Cancer J"},{"issue":"4","key":"535_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/14656566.2024.2333376","volume":"25","author":"EA Martino","year":"2024","unstructured":"Martino EA, Vigna E, Bruzzese A, Labanca C, Mendicino F, Lucia E, et al. Selinexor in multiple myeloma. Expert Opin Pharmacother. 2024;25(4):421\u201334. 2024.2333376 PubMed PMID: 38503547.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"535_CR35","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1038\/s41598-024-62852-z","volume":"14","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang R, Feng H, Du Y, Yang B, Zhang M, et al. Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database. Sci Rep. 2024;14(1):12231. https:\/\/doi.org\/10.1038\/s41598-024-62852-z.","journal-title":"Sci Rep"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00535-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:52:21Z","timestamp":1788475941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00535-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00535-6","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"111"}}